BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Emel Pamuk G, Sonsuz A. N-Acetylcysteine in The Treatment Of Non-Alcoholic Steatohepatitis. Journal of Gastroenterology and Hepatology 2003;18:1220-1. [DOI: 10.1046/j.1440-1746.2003.03156.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Goonetilleke M, Kuk N, Correia J, Hodge A, Moore G, Gantier MP, Yeoh G, Sievert W, Lim R. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells. Stem Cell Res Ther 2021;12:429. [PMID: 34321089 DOI: 10.1186/s13287-021-02476-6] [Reference Citation Analysis]
2 Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:679-692. [PMID: 20415840 DOI: 10.1111/j.1365-2036.2009.04230.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 65] [Article Influence: 11.5] [Reference Citation Analysis]
3 Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD004996. [PMID: 17253535 DOI: 10.1002/14651858.CD004996.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
4 Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014;20:569-577. [PMID: 24574727 DOI: 10.3748/wjg.v20.i2.569] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
5 Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19:6911-6918. [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911] [Cited by in CrossRef: 191] [Cited by in F6Publishing: 160] [Article Influence: 27.3] [Reference Citation Analysis]
6 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
7 Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 2009;87:679-695. [PMID: 19352614 DOI: 10.1007/s00109-009-0464-1] [Cited by in Crossref: 188] [Cited by in F6Publishing: 158] [Article Influence: 15.7] [Reference Citation Analysis]
8 Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014;2014:637027. [PMID: 25371775 DOI: 10.1155/2014/637027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 12.4] [Reference Citation Analysis]
9 Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc. 2019;78:290-304. [PMID: 30924429 DOI: 10.1017/s0029665119000570] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
10 Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005;17:636-641. [PMID: 16160540 DOI: 10.1097/01.mop.0000172816.79637.c5] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 5.7] [Reference Citation Analysis]
11 Franklin R, Bispo RFM, Sousa-Rodrigues CF, Pires LAS, Fonseca A Jr, Babinski MA. Grape Leucoanthocyanidin Protects Liver Tissue in Albino Rabbits with Nonalcoholic Hepatic Steatosis. Cells Tissues Organs 2018;205:129-36. [PMID: 29913455 DOI: 10.1159/000489166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
12 Tahan V, Eren F, Avsar E, Yavuz D, Yuksel M, Emekli E, Imeryuz N, Celikel C, Uzun H, Haklar G. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci. 2007;52:3465-3472. [PMID: 17436085 DOI: 10.1007/s10620-007-9756-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
13 Al-Busafi SA, Bhat M, Wong P, Ghali P, Deschenes M. Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat. 2012;2012:947575. [PMID: 23227320 DOI: 10.1155/2012/947575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
14 Anderson N, Borlak J. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacol Rev 2008;60:311-57. [DOI: 10.1124/pr.108.00001] [Cited by in Crossref: 260] [Cited by in F6Publishing: 233] [Article Influence: 20.0] [Reference Citation Analysis]
15 Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther. 2014;31:30-43. [PMID: 24385405 DOI: 10.1007/s12325-013-0084-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
16 Corrado RL, Torres DM, Harrison SA. Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 2014;98:55-72. [DOI: 10.1016/j.mcna.2013.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
17 Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Annals of Hepatology 2009;8:S51-9. [DOI: 10.1016/s1665-2681(19)31827-7] [Cited by in Crossref: 26] [Article Influence: 2.2] [Reference Citation Analysis]
18 Gallego-Durán R, Ampuero J, Funuyet J, Romero-Gómez M. [Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?]. Gastroenterol Hepatol. 2013;36:587-596. [PMID: 24011648 DOI: 10.1016/j.gastrohep.2013.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-1058. [PMID: 15625647 DOI: 10.1016/s1542-3565(04)00440-9] [Cited by in Crossref: 255] [Cited by in F6Publishing: 107] [Article Influence: 15.9] [Reference Citation Analysis]
20 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 318] [Article Influence: 40.7] [Reference Citation Analysis]
21 Dludla PV, Nkambule BB, Mazibuko-Mbeje SE, Nyambuya TM, Marcheggiani F, Cirilli I, Ziqubu K, Shabalala SC, Johnson R, Louw J, Damiani E, Tiano L. N-Acetyl Cysteine Targets Hepatic Lipid Accumulation to Curb Oxidative Stress and Inflammation in NAFLD: A Comprehensive Analysis of the Literature. Antioxidants (Basel) 2020;9:E1283. [PMID: 33339155 DOI: 10.3390/antiox9121283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
22 Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-49. [PMID: 17845148 DOI: 10.1517/14728222.11.9.1231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
23 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
24 Koehler E, Watt K, Charlton M. Fatty Liver and Liver Transplantation. Clinics in Liver Disease 2009;13:621-30. [DOI: 10.1016/j.cld.2009.07.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
25 Mardinoglu A, Ural D, Zeybel M, Yuksel HH, Uhlén M, Borén J. The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients 2019;11:E1578. [PMID: 31336926 DOI: 10.3390/nu11071578] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
26 Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587-96. [PMID: 19412008 DOI: 10.1097/MPG.0b013e31818e04d1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
27 Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011;31:1432-1448. [PMID: 22093324 DOI: 10.1111/j.1478-3231.2011.02604.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 97] [Article Influence: 12.9] [Reference Citation Analysis]
28 van der Poorten D, George J. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int 2007;1:343-54. [PMID: 19669329 DOI: 10.1007/s12072-007-9011-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
29 Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79-104. [PMID: 20578268 DOI: 10.1002/hep.23623] [Cited by in Crossref: 370] [Cited by in F6Publishing: 320] [Article Influence: 33.6] [Reference Citation Analysis]
30 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
31 Oliveira CP, Cotrim HP, Stefano JT, Siqueira ACG, Salgado ALA, Parise ER. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. Arq Gastroenterol 2019;56:184-90. [PMID: 31460584 DOI: 10.1590/S0004-2803.201900000-36] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
32 Aljohani W, Chan BPH, Yaghoobi M. Role of N-Acetylcysteine in the Treatment of Acute Nonacetaminophen, Nonalcoholic and Nonviral Hepatitis: A Meta-analysis. J Can Assoc Gastroenterol 2021;4:125-30. [PMID: 34056530 DOI: 10.1093/jcag/gwaa017] [Reference Citation Analysis]
33 Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis. 2012;16:631-645. [PMID: 22824485 DOI: 10.1016/j.cld.2012.05.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
34 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708. [PMID: 20955971 DOI: 10.1016/j.bpg.2010.08.005] [Cited by in Crossref: 128] [Cited by in F6Publishing: 107] [Article Influence: 12.8] [Reference Citation Analysis]
35 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 2010;57:85-140. [DOI: 10.1016/j.yapd.2010.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
36 Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention. J Surg Res. 2011;167:96-112. [PMID: 20400112 DOI: 10.1016/j.jss.2009.10.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]